射波刀配合贝伐单抗及替莫唑胺治疗复发高级别胶质瘤的疗效及安全性

The efficacy and safety of CyberKnife combined with bevacizumab and temozolomide in the treatmenting of recurrently high-grade glioma

目的:对比分析射波刀配合贝伐单抗联合替莫唑胺治疗复发高级别胶质瘤(r-HGG)的疗效及安全性。方法:选取就诊于解放军总医院第六医学中心肿瘤诊疗中心的67例r-HGG患者,按随机数表法将其分为观察组(37例)和对照组(30例),观察组采用射波刀配合贝伐单抗+替莫唑胺治疗,对照组采用射波刀仅配合贝伐单抗治疗,评估治疗后两组患者临床疗效、生活质量改善、不良反应情况以及总生存情况。结果:观察组和对照组中位生存期分别为12个月和10个月,其差异有统计学意义(x^2=4.905,P<0.05);观察组临床控制率为94.6%,高于对照组的86.7%,但差异无统计学意义;两组临床症状改善率比较差异无统计学意义,两组均未观察到严重不良反应。结论:射波刀配合贝伐单抗+替莫唑胺治疗r-HGG能够提高总生存期,且能改善临床症状,同时不增加严重不良反应。

Objective:To contrastively analyze the efficacy and safety that CyberKnife combined with bevacizumab and temozolomide in treating recurrently high-grade glioma.Methods:67 patients with recurrently high-grade gliomas who admitted to the Sixth Medical Center of Chinese PLA General Hospital were selected and were randomly divided into observation group(37 cases)and control group(30 cases).The observation group adopted CyberKnife combined with bevacizumab+temozolomide to implement treatment,while the control group adopted CyberKnife only combined with bevacizumab to implement treatment.The clinical efficacy,quality of life improvement,adverse reactions and overall survival post treatment of two groups were assessed.Results:The median survival time of two groups were 12 and 10 months,respectively,and the difference of that between two groups was statistically significant(x^2=4.905,P<0.05).The clinical control rate of the observation group was 94.6%,which was higher than 86.7%of the control group,but the difference was not statistically significant.And there was no significant difference in the improvement rate of clinical symptoms between the two groups,and the serious adverse reactions didn’t be observed in both two groups.Conclusion:CyberKnife combined with bevacizumab and temozolomide in the treatment of recurrently high-grade glioma can enhance the overall survival,and improve the clinical symptoms,and this method does not increase the serious adverse reactions.